Evidence map›Paper›PMID 18268926›Full record

ReviewInternational journal of chronic obstructive pulmonary disease2007

Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions.

Khaled Albouaini, Mohammed Andron, Albert Alahmar, Mohaned Egred

Open access · greenAbstract readReview
PubMed Full text at PMC
In one paragraph

Review in International journal of chronic obstructive pulmonary disease, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 3 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 77 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. A Systematic Review on Cannabis Hyperemesis Syndrome and Its Management Options.Medical principles and practice : international journal of the Kuwait University, Health Science Centre
    Pooled it
  4. Observational
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Beta-blocker Use in Moderate and Severe Chronic Obstructive Pulmonary Disease.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2019
    Article
  15. Cardiovascular disease and COPD: dangerous liaisons?European respiratory review : an official journal of the European Respiratory Society · 2018
    Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Khaled AlbouainiCardiothoracic Centre, Liverpool, England, UK.
Mohammed Andron
Albert Alahmar
Mohaned Egred
Essex Cardiothoracic Centre · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mortality and incidence of chronic obstructive pulmonary disease (COPD) and coronary heart disease increase with age. Despite the clear evidence of beta blockers (BBs) effectiveness, there is a general reluctance to use them in patients with COPD due to a perceived contraindication and fear of inducing adverse reactions and bronchspasm. BBs are well tolerated in patients with cardiac disease and concomitant COPD with no evidence of worsening of respiratory symptoms or FEV1, and the safety of BBs in patients with COPD has been demonstrated, but their use in this group of patients remains low. The cumulative evidence from trials and meta-analysis indicates that cardioselective BBs should not be withheld in patients with reactive airway disease or COPD. Patients with COPD have a high incidence of cardiac events necessitating careful consideration of prophylactic treatment. The benefits of beta blockade in this group appear to outweigh any potential risk of side effects according to the available evidence. In this article, we will discuss the use of BBs in patients with COPD and review the evidence for their use and safety in this group of patients.

Indexed as

Pulmonary Disease, Chronic ObstructiveAdrenergic beta-AntagonistsCardiovascular DiseasesEvidence-Based MedicineHumansUnited KingdomAdrenergic beta-Antagonists

Identifiers

PMID18268926
PMCPMC2699954
OpenAlexW162001258

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.